Spondyloarthropathies News

The emergence of biosimilar TNF inhibitors in Poland led to reduced prices and expenditures, but little improvements in treatment availability, according to data published in Annals of the Rheumatic Diseases.

Patients with axial spondyloarthritis and psoriatic arthritis routinely “bounce” from one provider to the next for years before finally receiving the correct diagnosis in a rheumatology clinic, according to experts.

The introduction of TNF inhibitors in 2003 has failed to stop fracture rates in patients with ankylosing spondylitis from more than doubling from 2000 to 2020, according to data published in Arthritis Care & Research.

The FDA has granted final approval to Zydus Lifesciences to manufacture and market generic indomethacin 50 mg suppositories, according to a company press release.

AUSTIN, Texas — A former NBA mascot encouraged attendees of the 2023 Rheumatology Nurses Society annual conference to make the most of every moment they have with their patients, as their time and empathy can make all the difference.

Lower back pain remains the leading global cause of years lived with disability, while projections estimate that more than 800 million people will experience lower back pain by 2050, according to data published in The Lancet Rheumatology.

Patients with autoimmune diseases or long COVID who used a personalized digital care program alongside other non-pharmacologic strategies were more likely to achieve better health-related quality of life scores, according to data.

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what has been the top selling drug in the country.

Patients with immune checkpoint inhibitor-associated inflammatory arthritis who receive a biologic DMARD demonstrate quicker arthritis control, but also experience faster cancer progression, vs. methotrexate, according to data.

Patients with anxiety or depression are less likely to exhibit healthy self-management for their rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis, according to data presented at EULAR 2023 Congress.